CN112789043A - 防治nitm 的药物组合物及其医药用途 - Google Patents
防治nitm 的药物组合物及其医药用途 Download PDFInfo
- Publication number
- CN112789043A CN112789043A CN201880098058.0A CN201880098058A CN112789043A CN 112789043 A CN112789043 A CN 112789043A CN 201880098058 A CN201880098058 A CN 201880098058A CN 112789043 A CN112789043 A CN 112789043A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- eye
- atropine
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000004349 nearwork-induced transient myopia Effects 0.000 title claims abstract description 99
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 90
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims abstract description 57
- 229930003347 Atropine Natural products 0.000 claims abstract description 56
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims abstract description 56
- 229960000396 atropine Drugs 0.000 claims abstract description 56
- 150000003839 salts Chemical class 0.000 claims abstract description 46
- 239000003814 drug Substances 0.000 claims abstract description 31
- 239000000203 mixture Substances 0.000 claims abstract description 27
- 239000004327 boric acid Substances 0.000 claims abstract description 17
- 238000009472 formulation Methods 0.000 claims abstract description 17
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 12
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229940079593 drug Drugs 0.000 claims abstract description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims abstract description 6
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims abstract description 6
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims abstract description 5
- 235000019799 monosodium phosphate Nutrition 0.000 claims abstract description 5
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims abstract description 5
- 239000003889 eye drop Substances 0.000 claims description 85
- 229940012356 eye drops Drugs 0.000 claims description 66
- 208000001491 myopia Diseases 0.000 claims description 65
- 235000002639 sodium chloride Nutrition 0.000 claims description 53
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical group [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 claims description 50
- 229960002028 atropine sulfate Drugs 0.000 claims description 50
- 230000004379 myopia Effects 0.000 claims description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 239000006196 drop Substances 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 230000003204 osmotic effect Effects 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 7
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 7
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 239000002562 thickening agent Substances 0.000 claims description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- 229960003943 hypromellose Drugs 0.000 claims description 4
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 3
- 239000000022 bacteriostatic agent Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229920000289 Polyquaternium Polymers 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 229910021538 borax Inorganic materials 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical group [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 claims description 2
- 239000003885 eye ointment Substances 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000012669 liquid formulation Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 235000013772 propylene glycol Nutrition 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 239000004328 sodium tetraborate Substances 0.000 claims description 2
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 239000000463 material Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 39
- 230000004438 eyesight Effects 0.000 description 25
- 238000012360 testing method Methods 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 15
- 239000008186 active pharmaceutical agent Substances 0.000 description 12
- 239000011521 glass Substances 0.000 description 12
- 239000008215 water for injection Substances 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 11
- 239000002504 physiological saline solution Substances 0.000 description 9
- 210000001747 pupil Anatomy 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 230000004436 pseudomyopia Effects 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 201000009310 astigmatism Diseases 0.000 description 7
- 238000012937 correction Methods 0.000 description 7
- 201000000255 cycloplegia Diseases 0.000 description 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 7
- 230000004493 normal intraocular pressure Effects 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 229940124274 edetate disodium Drugs 0.000 description 4
- 230000004515 progressive myopia Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000002911 mydriatic effect Effects 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 206010020675 Hypermetropia Diseases 0.000 description 2
- 230000004308 accommodation Effects 0.000 description 2
- 230000002350 accommodative effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000695 crystalline len Anatomy 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000004305 hyperopia Effects 0.000 description 2
- 201000006318 hyperopia Diseases 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000004423 myopia development Effects 0.000 description 2
- 201000010041 presbyopia Diseases 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- -1 1.5% Chemical compound 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010073286 Pathologic myopia Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000003618 borate buffered saline Substances 0.000 description 1
- 229960002645 boric acid Drugs 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000036040 emmetropia Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于医药领域，涉及一种防治NITM的药物组合物及其医药用途。具体地，所述药物组合物为眼用药物组合物例如眼用制剂。具体地，本发明涉及一种药物组合物，其包含0.001％－0.2％的阿托品或其可药用盐，以及一种或多种药学上可接受的辅料；其中，所述药物组合物的pH值为4.0－6.5；所述药物组合物包含0.5％－5％的pH调节剂，所述pH调节剂选自磷酸二氢钠、磷酸氢二钠、枸橼酸、枸橼酸盐、硼酸和硼酸盐中的任意一种或多种。本发明的药物组合物能够有效地治疗和/或预防NITM，具有良好的应用前景。
Description
PCT国内申请，说明书已公开。
Claims (23)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018111198993 | 2018-09-25 | ||
| CN201811119899.3A CN109157503B (zh) | 2018-09-25 | 2018-09-25 | 防治nitm的药物组合物及其医药用途 |
| PCT/CN2018/113969 WO2020062445A1 (zh) | 2018-09-25 | 2018-11-05 | 防治nitm的药物组合物及其医药用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112789043A true CN112789043A (zh) | 2021-05-11 |
Family
ID=64880499
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910638033.1A Active CN110934869B (zh) | 2018-09-25 | 2018-09-25 | 一种阿托品药物组合物和药盒产品 |
| CN201811119899.3A Active CN109157503B (zh) | 2018-09-25 | 2018-09-25 | 防治nitm的药物组合物及其医药用途 |
| CN201880098058.0A Pending CN112789043A (zh) | 2018-09-25 | 2018-11-05 | 防治nitm 的药物组合物及其医药用途 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910638033.1A Active CN110934869B (zh) | 2018-09-25 | 2018-09-25 | 一种阿托品药物组合物和药盒产品 |
| CN201811119899.3A Active CN109157503B (zh) | 2018-09-25 | 2018-09-25 | 防治nitm的药物组合物及其医药用途 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210259961A1 (zh) |
| EP (1) | EP3858353B1 (zh) |
| JP (1) | JP7359204B2 (zh) |
| CN (3) | CN110934869B (zh) |
| WO (1) | WO2020062445A1 (zh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110974970A (zh) * | 2019-12-31 | 2020-04-10 | 杭州赫尔斯科技有限公司 | 复方药物组合物滴眼液、其制备方法和应用 |
| CN111358771B (zh) * | 2020-04-14 | 2023-01-10 | 沈阳药科大学 | 一种硫酸阿托品眼用膜剂及其制备方法 |
| CN111821259A (zh) * | 2020-07-14 | 2020-10-27 | 艾尔健康眼药(辽宁)有限公司 | 一种眼用药物组合物 |
| CN114306331B (zh) * | 2020-10-10 | 2023-07-18 | 远大生命科学(武汉)有限公司 | 戊乙奎醚在治疗或预防视力损伤性眼部疾病中的用途 |
| CN114668762B (zh) * | 2020-12-24 | 2024-04-16 | 江苏恒瑞医药股份有限公司 | 一种药物组合物 |
| EP4088713A1 (en) * | 2021-05-10 | 2022-11-16 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | Ophthalmic pharmaceutical composition comprising atropine |
| CN113440486B (zh) * | 2021-06-02 | 2022-12-20 | 苏州欧康维视生物科技有限公司 | 一种用于预防或治疗眼科疾病的滴眼剂组合物及其制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107456440A (zh) * | 2017-08-07 | 2017-12-12 | 杭州赫尔斯科技有限公司 | 一种低浓度阿托品类药物滴眼液及其制备方法 |
| CN108338969A (zh) * | 2018-02-08 | 2018-07-31 | 胡敏 | 一种低浓度托烷类药物滴眼液及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101049287A (zh) * | 2006-04-07 | 2007-10-10 | 财团法人长庚纪念医院 | 抑制近视度数增加的低浓度阿托平眼药剂及其制造方法 |
| US20070254914A1 (en) * | 2006-05-01 | 2007-11-01 | Non-Profit Organization Chang Gung Memorial Hospital | Low-concentration atropine solution for preventing myopia progression and preparing method thereof |
| JP6346088B2 (ja) * | 2011-06-15 | 2018-06-20 | ビジョネーリング テクノロジーズ、インコーポレイテッド | 近視の進行を治療するための眼科用レンズ |
| US9421199B2 (en) * | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
-
2018
- 2018-09-25 CN CN201910638033.1A patent/CN110934869B/zh active Active
- 2018-09-25 CN CN201811119899.3A patent/CN109157503B/zh active Active
- 2018-11-05 JP JP2021516570A patent/JP7359204B2/ja active Active
- 2018-11-05 WO PCT/CN2018/113969 patent/WO2020062445A1/zh unknown
- 2018-11-05 EP EP18934879.0A patent/EP3858353B1/en active Active
- 2018-11-05 CN CN201880098058.0A patent/CN112789043A/zh active Pending
- 2018-11-05 US US17/279,555 patent/US20210259961A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107456440A (zh) * | 2017-08-07 | 2017-12-12 | 杭州赫尔斯科技有限公司 | 一种低浓度阿托品类药物滴眼液及其制备方法 |
| CN108338969A (zh) * | 2018-02-08 | 2018-07-31 | 胡敏 | 一种低浓度托烷类药物滴眼液及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3858353A1 (en) | 2021-08-04 |
| CN109157503B (zh) | 2019-08-16 |
| JP7359204B2 (ja) | 2023-10-11 |
| JP2022502375A (ja) | 2022-01-11 |
| EP3858353B1 (en) | 2024-02-07 |
| WO2020062445A1 (zh) | 2020-04-02 |
| CN110934869A (zh) | 2020-03-31 |
| CN110934869B (zh) | 2023-07-04 |
| US20210259961A1 (en) | 2021-08-26 |
| EP3858353A4 (en) | 2022-07-06 |
| CN109157503A (zh) | 2019-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110934869B (zh) | 一种阿托品药物组合物和药盒产品 | |
| RU2630968C2 (ru) | Лекарственные средства и способы лечения пресбиопии, умеренной гиперметропии и неправильного астигматизма | |
| RU2651046C2 (ru) | Композиции для лечения сухости глаза | |
| CN107456440A (zh) | 一种低浓度阿托品类药物滴眼液及其制备方法 | |
| CN102014869A (zh) | 治疗或预防眼痛的酮咯酸氨丁三醇组合物 | |
| CN110974970A (zh) | 复方药物组合物滴眼液、其制备方法和应用 | |
| JP2022536662A (ja) | 多焦点性を作り出すために偽水晶体患者において副交感神経刺激薬を単独でまたは１種類もしくは複数種類のαアゴニストと組み合わせて使用する方法 | |
| CN112426405A (zh) | 预防及控制近视发展的药物组合物、滴眼液及其制备方法与应用 | |
| CN111803441A (zh) | 一种含0.01%阿托品的玻璃酸钠滴眼液及其制备方法 | |
| Mazor et al. | Piloplex, a new long-acting pilocarpine polymer salt. B: Comparative study of the visual effects of pilocarpine and Piloplex eye drops. | |
| CN114796205B (zh) | 用于治疗近视的方法和药物组合物 | |
| EP4342472A1 (en) | Eye drop for suppressing myopia | |
| JPWO2020087021A5 (zh) | ||
| CN117979951A (zh) | 一种用于缓解眼部疼痛的硫酸软骨素的用途 | |
| CN116785290B (zh) | 苯环喹溴铵及其异构体在制备眼用制剂中的应用 | |
| US10350232B1 (en) | Medicinal drops | |
| Li et al. | Comparison of low concentration atropine eye drops with different concentrations and administration frequencies in controlling the progression of myopia in children | |
| CN112716978A (zh) | 一种复方阿托品类药物滴眼液及其制备方法与应用 | |
| KR20230051154A (ko) | 스핑고신-1-포스페이트 수용체 조절제인 핑골리모드 및 이의 유도체를 이용한 근시의 예방 및 치료를 위한 방법 및 조성물 | |
| CN114177182A (zh) | 枸橼酸西地那非/他达拉非/伐地那非在制备治疗近视药物中的应用 | |
| Nanji et al. | High-Dose Steroids and Pentoxifylline in Methanol Induced Optic Neuropathy: A Case Report and Review of the Literature | |
| KR20230051152A (ko) | β2-아드레날린 수용체 효능제인 페노테롤 하이드로브로마이드 및 이의 유도체를 이용한 근시의 예방 및 치료를 위한 방법 및 조성물 | |
| TW202337462A (zh) | 採用長春西汀治療近視的方法 | |
| KR20230051155A (ko) | 베르베리다세아엔 알칼로이드인 베르베린 및 이의 유도체를 이용한 근시의 예방 및 치료를 위한 방법 및 조성물 | |
| KR20230051153A (ko) | 히스톤 데아세틸레이스(hdac) 저해제인 트라이코스타틴 a 및 이의 유도체를 이용한 근시의 예방 및 치료를 위한 방법 및 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Ningli Inventor after: Liu Jidong Inventor after: Guo Lei Inventor after: Yang Qiang Inventor after: Gao Kun Inventor after: Li Linwei Inventor after: Gu Hong Inventor after: Sun Yang Inventor after: Fu Le Inventor before: Liu Jidong Inventor before: Wang Ningli Inventor before: Guo Lei Inventor before: Yang Qiang Inventor before: Gao Kun Inventor before: Li Linwei Inventor before: Gu Hong Inventor before: Sun Yang Inventor before: Fu Le |
|
| CB03 | Change of inventor or designer information | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: No. 25, New Canal Road, Shenyang Area, China (Liaoning) Pilot Free Trade Zone, Hunnan District, Shenyang, Liaoning 110167 Applicant after: SHENYANG XINGQI PHARMACEUTICAL Co.,Ltd. Address before: 110163 Surabaya street, Dongling District, Shenyang, Liaoning Province, No. 68 Applicant before: SHENYANG XINGQI PHARMACEUTICAL Co.,Ltd. |
|
| CB02 | Change of applicant information |